Corporate | Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank
(WorldNews France)

Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank Proceeds will be used to speed up development of pioneering lead product NBTXR3 and to support the European go-to-market strategy Paris, France and Cambridge, Massachusetts, October 16, 2018 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company received an initial 16 million euros as the first disbursement under the previously announced non-dilutive loan from the European Investment Bank (EIB). The financing agreement, which will reach a total of 40 million...